GH Research (NASDAQ:GHRS) Trading 6.5% Higher - What's Next?

Key Points

• GH Research’s stock price rose 6.5% to a last trading price of $12.72, despite a significant drop in trading volume.
• Analysts have generally rated the stock as a Moderate Buy, with price targets ranging from $25.00 to $39.00.
• The company reported earnings of ($0.15) per share for the last quarter, outperforming analysts' expectations, with projected fiscal year EPS at -0.8.

GH Research PLC (NASDAQ:GHRS - Get Free Report) shares traded up 6.5% during trading on Monday . The company traded as high as $12.68 and last traded at $12.72. 42,165 shares were traded during trading, a decline of 87% from the average session volume of 322,760 shares. The stock had previously closed at $11.94.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. Zacks Research downgraded shares of GH Research from a "strong-buy" rating to a "hold" rating in a report on Wednesday, August 13th. Cantor Fitzgerald assumed coverage on shares of GH Research in a report on Wednesday, June 4th. They set an "overweight" rating and a $25.00 price objective for the company. Wall Street Zen raised shares of GH Research from a "sell" rating to a "hold" rating in a report on Saturday, July 5th. Finally, JMP Securities reaffirmed a "market outperform" rating and set a $39.00 price objective on shares of GH Research in a report on Tuesday, June 24th. Seven research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $32.00.

GH Research Price Performance

The stock has a market capitalization of $693.56 million, a P/E ratio of -18.01 and a beta of 0.97. The firm's 50 day moving average price is $13.83 and its 200 day moving average price is $12.22.

GH Research (NASDAQ:GHRS - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.07. On average, equities research analysts forecast that GH Research PLC will post -0.8 earnings per share for the current year.

Hedge Funds Weigh In On GH Research

Hedge funds and other institutional investors have recently modified their holdings of the stock. BNP Paribas Financial Markets purchased a new position in shares of GH Research during the fourth quarter valued at about $44,000. Osaic Holdings Inc. increased its position in shares of GH Research by 63.6% during the second quarter. Osaic Holdings Inc. now owns 6,175 shares of the company's stock valued at $75,000 after buying an additional 2,400 shares during the period. JPMorgan Chase & Co. purchased a new position in shares of GH Research during the second quarter valued at about $79,000. Virtus Investment Advisers LLC purchased a new position in shares of GH Research during the second quarter valued at about $89,000. Finally, Two Sigma Investments LP purchased a new position in shares of GH Research during the fourth quarter valued at about $117,000. Hedge funds and other institutional investors own 56.90% of the company's stock.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).